Business Context and Reporting Period
This Form 6-K filing is submitted by pSivida Limited, a foreign issuer, for the month of April 2005. The report was signed on April 8, 2005, by Aaron Finlay, Chief Financial Officer and Company Secretary. The registrant's principal executive offices are located in Perth, Western Australia.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes and Corporate Events
The primary content of this filing is the announcement that pSivida Limited is expanding the market for its lead cancer product, BrachySilTM. No financial material changes versus prior periods are detailed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the strategic expansion of the BrachySilTM product line. The filing does not contain specific financial guidance, outlook projections, risk factors, contingencies, or details on unusual items.
Investor Verification Checklist
- Verify the specific details and scope of the market expansion for BrachySilTM referenced in Exhibit 99.1.
- Confirm the commercial status and regulatory approvals for BrachySilTM in the new markets.
- Review subsequent filings for financial impact resulting from this expansion.